- Sanofi‘s Q1 business EPS beat estimates at EU 1.78, surpassing the estimated EU 1.77.
- The company experienced a -7.4% in Business EPS excluding foreign exchange impacts.
- Sales reached EU 10.46 billion, marking a 2.4% increase year on year, exceeding the estimate of EU 10.3 billion.
- Dupixent net product sales amounted to EU 2.84 billion, slightly above the estimated EU 2.83 billion.
- Beyfortus net sales stood at EU 182 million, marginally over the estimated EU 181.4 million.
- Biopharma reported net sales of EU 8.94 billion, higher than the estimated EU 8.8 billion.
- Consumer healthcare sales came to EU 1.53 billion, surpassing the estimated EU 1.5 billion.
- Vaccine sales reached EU 1.18 billion, slightly above the estimated EU 1.17 billion.
- Influenza vaccines alone sold EU 73 million, exceeding the estimated sales of EU 61.9 million.
- Aubagio net sales were EU 102 million, lower than the estimate of EU 110.8 million.
- Sales at constant exchange rates increased by 6.7%, Dupixent sales ex-FX increased by 24.9%, Beyfortus sales ex-FX remained stable, Biopharma sales ex-FX increased 6.3%, Consumer healthcare sales ex-FX increased 9%, Vaccine sales ex-FX increased 5.6%, Aubagio sales ex-FX decreased 74.7%.
- Business net income reached EU 2.22 billion, slightly beating the estimate of EU 2.21 billion.
- Business operating income totalled EU 2.84 billion, surpassing the estimated EU 2.8 billion.
- Consumer healthcare business operating income was EU 472 million, a decrease of 12% y/y, falling short of the estimated EU 492.2 million.
- Biopharma Business operating income totalled EU 2.37 billion, a decrease of 15% y/y, falling short of the estimated EU 2.48 billion.
- Gross margin was 73.5%, lower than the previous year’s 76.1% and the estimated 74.4%.
- Consumer healthcare gross margin stood at 63.9%, lower than the previous year’s 67% and the estimate of 67%.
- Biopharma gross margin was 75.1%, lower than the previous year’s 77.7% and the estimate of 77.5%.
- R&D expenses increased by 10% y/y to EU 1.72 billion, narrowly surpassing the estimated EU 1.71 billion.
- The company reported a negative free cash flow of EU 309 million compared to positive EU 1.54 billion the previous year.
- Sanofi forecasts business EPS for 2024 to remain relatively stable, excluding the impact of an expected tax increase to 21%.
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi, a pharmaceutical company with a global presence, is expected to maintain a steady performance in the long run, based on Smartkarma Smart Scores. The company scores well in key areas such as Dividend and Resilience, indicating a strong financial position and ability to withstand market challenges. While its Value and Growth scores are moderately positive, suggesting room for improvement in these aspects, Sanofi‘s overall outlook remains stable.
With a solid foundation in prescription pharmaceuticals and vaccines, along with a diverse portfolio including medications for cardiovascular, metabolic disorders, and oncology, Sanofi is positioned to continue serving a wide range of customers globally. Although there is room for growth and enhancing momentum, the company’s focus on resilience and dividends provides a sense of stability for investors evaluating its long-term prospects.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
